EMEA-001830-PIP01-15-M01
Key facts
Invented name |
|
Active substance |
Pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)
|
Therapeutic area |
Vaccines
|
Decision number |
P/0260/2018
|
PIP number |
EMEA-001830-PIP01-15-M01
|
Pharmaceutical form(s) |
Suspension for injection
|
Condition(s) / indication(s) |
Prevention of influenza infection
|
Route(s) of administration |
Intramuscular use
|
Contact for public enquiries |
Seqirus S.r.l.
E-mail: pip.seq@seqirus.com |
Decision type |
PM: decision on the application for modification of an agreed PIP
|